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Abstract
Background: Cowden Syndrome (CS) patients with germ line point mutations in the PTEN gene are at high risk
for developing breast cancer. It is believed that cells harboring these mutant PTEN alleles are predisposed to
malignant conversion. This article will characterize the biochemical and biological properties of a mutant PTEN
protein found in a commonly used metastatic breast cancer cell line.
Methods: The expression of PTEN in human breast carcinoma cell lines was evaluated by Western blotting
analysis. Cell line MDA-MB-453 was selected for further analysis. Mutation analysis of the PTEN gene was carried out
using DNA isolated from MDA-MB-453. Site-directed mutagenesis was used to generate a PTEN E307K mutant
cDNA and ectopic expressed in PC3, U87MG, MCF7 and Pten-/- mouse embryo fibroblasts (MEFS). Histidine (His)-
tagged PTEN fusion protein was generated in Sf9 baculovirus expression system. Lipid phosphatase and
ubiquitination assays were carried out to characterize the biochemical properties of PTEN E307K mutant. The
intracellular localization of PTEN E307K was determined by subcellular fractionation experiments. The ability of PTEN
E307K to alter cell growth, migration and apoptosis was analyzed in multiple PTEN-null cell lines.
Results: We found a mutation in the PTEN gene at codon 307 in MDA-MB-453 cell line. The glutamate (E) to lysine
(K) substitution rendered the mutant protein to migrate with a faster mobility on SDS-PAGE gels. Biochemically, the
PTEN E307K mutant displayed similar lipid phosphatase and growth suppressing activities when compared to wild-
type (WT) protein. However, the PTEN E307K mutant was present at higher levels in the membrane fraction and
suppressed Akt activation to a greater extent than the WT protein. Additionally, the PTEN E307K mutant was
polyubiquitinated to a greater extent by NEDD4-1 and displayed reduced nuclear localization. Finally, the PTEN
E307K mutant failed to confer chemosensitivity to cisplatinum when re-expressed in Pten-/- MEFS.
Conclusions: Mutation at codon 307 in PTEN C2 loop alters its subcellular distribution with greater membrane
localization while being excluded from the cell nucleus. This mutation may predispose breast epithelial cells to
malignant transformation. Also, tumor cells harboring this mutation may be less susceptible to the cytotoxic effects
of chemotherapeutics.
Background
Germ line mutations in the PTEN gene are present in
80% of Cowden Syndrome (CS), and in 60% of Banna-
yan-Riley-Ruvalcaba syndrome (BBRS) [1]. CS patients
are predisposed to breast, thyroid, skin, and endometrial
malignancies [2]. PTEN mutations are found scattered
along exon 1 to 8 in both CS and BBRS patients. Signifi-
cant numbers of mutations (>30%) are found in exon 5
affecting codon 123-131 within the core catalytic
domain [3]. However, germ-line mutation in the PTEN
gene is uncommon in early onset (<40 year old) breast
cancer patients with wild-type BRCA1 allele [4].
Although the loss of heterozygosity at chromosome
10q23 region has been reported in 17 out of 42 (40%) of
invasive breast carcinomas, PTEN mutations in sporadic
breast carcinomas are rare [5-7]. However, PTEN may
still play a role in sporadic breast cancer due to its
reduced expression [8].
The PTEN gene encodes a 54 kDa lipid phosphatase
with specificity towards phosphatidylinositol (3,4,5) tri-
phosphate (PIP3) [9]. The 185-amino acid (aa) catalytic
* Correspondence: axchan@mcw.edu
2Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow
Transplant, Medical College of Wisconsin, 8701, Watertown Plank Road,
Milwaukee WI 53226, USA
Full list of author information is available at the end of the article
Singh et al. BMC Cancer 2011, 11:490
http://www.biomedcentral.com/1471-2407/11/490
© 2011 Singh et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
domain in the amino(N)-terminus is followed by a phos-
pholipid-binding C2 domain between aa186-353. PTEN
C2 domain resembles that of the Ca2+-independent
membrane recruitment motif found in Protein Kinase C
isotypes [10]. While the membrane-facing side of C2
domain is characterized by the polybasic CBRIII loop
between aa260-269, the cytosolic-facing portion features
an unstructured region of 33-aa between codon 282-
314, referred to as the C2 loop [11]. Interestingly, codon
Lys289 (K289) within the C2 loop is a target site for
mono-ubiquitination and is implicated in nuclear import
[12]. Additional ubiquitination sites have also been iden-
tified in the N-terminus but these sites are modified by
polyubiquitination and play a role in the stability of
PTEN through proteosome-mediated degradation [13].
These ubiquitination events have been shown to be cat-
alyzed by NEDD4-1, a ring domain containing E3 ligase
[13].
A mutation in the PTEN C2 loop has been identified
in a case of CS at codon K289 [12]. The K289E muta-
tion disrupts monoubiquitination and impedes PTEN
nuclear import. The resulting loss of growth suppression
may explain the numerous intestinal polyps found in
this patient. In this manuscript, we report the character-
ization of another C2 loop mutant uncovered during a
screen for aberrant PTEN protein expression in a panel
of human breast cancer cell lines.
Methods
Cell cultures
All cell lines were obtained from the cell bank of Dr.
Stuart Aaronson (Mount Sinai School of Medicine) and
maintained in DMEM supplemented with 10% FBS.
Pten-/- MEFS were a gift from Dr. Hong Wu (UCLA).
For transfection of 293T cells, 1 × 106 cells were trans-
fected in 100-mm plates with 10 μg of DNA using 12 μl
of Lipofectamine2000 (Invitrogen) in 6 ml of serum-
and antibiotic-free DMEM for 4 h. Cells were lysed after
48 h of incubation. For gene transfer in PC3 cells, 1 ×
105 cells per well in a 6-well plate were transfected with
2-4 μg of DNA using 2 μl of Lipofectamine2000 (Invi-
trogen) in 1 ml of serum- and antibiotic-free DMEM for
4 h. Cells were analyzed after 48 h incubation. For ret-
roviral gene transfer, 10 μg of pBabe-puro expression
vectors was co-transfected with either 10 μg of pCL-
ECO or pCL-AMPHO helper viral DNA for Pten-/-
MEFS and U87MG, respectively. Cultures were infected
with predetermined volume of viral supernatants to gen-
erate similar ectopic gene expression. After 6 h of incu-
bation, cells were selected in 1.0-1.5 μg/ml of
puromycin and marker-selected mass cultures were used
in subsequent analysis. For the electroporation of MCF7
cells, approximately 1.5 × 106 cells were electroporated
with 2 μg of expression plasmids using the nucleofection
kit according to the manufacturer’s instructions
(Amaxa). For lipofection of MCF7, approximately 3 ×
105 cells in 6-well plates were transfected with 2 μg of
plasmid DNA and 5 μl of lipofectamine 2000 (Invitro-
gen) for 6 h. Cells were analyzed after 24 to 48 h.
Sequencing analysis
cDNAs were generated from total RNA of MDA-MB-
453 using SuperScript® III First-Strand Synthesis System
(Invitrogen). PCR fragments were generated with the
following primer pairs covering the entire coding region
of PTEN: Exon1 and 2: P1 - 5’ atgacagccatcatcaaagagatc
3’, P8 - 5’ aatattgttcctgtatacgccttc 3’ Exon3 and 4: P16 -
5’ agacttgaaggcgtatacagg 3’, P76 - 5’ gtcatcttcacttagc-
cattggt 3’ Exon5: P26 - 5’ cccttttgtgaagatcttgac 3’, P41
-5’ cagtgccactggtctataatccag 3’ Exon6 and 7: P3 - 5’
ctggattatagaccagtggcactg 3’, P70 - 5’ ctgtttgtggaagaactc-
tac 3’ Exon8: P71 - 5’ gtagagttcttccacaaacag 3’, P24 - 5’
cagcttcaccttaaaatttgg 3’ Exon9: P34 - 5’ gccaaccga-
tacttttctccaaat 3’, P2a - 5’ tcagacttttgtaatttgtgtatg 3’
Amplified fragments were resolved on agarose gels and
PCR products were excised and purified by a gel extrac-
tion kit (Qiagen). Amplified products were subjected to
sequencing analysis using the primers listed above.
Expression plasmids
All expression plasmids have been reported previously
[14-16]. The PTEN E307K mutant plasmid was con-
structed using PCR-based site-directed mutagenesis and
cDNA was subcloned in the BamHI and EcoRI sites of
both pBabe-puro and pCEFL-KZ-AU5 expression
vectors.
Reagents
LY294002 and rapamycin were purchased from Sigma.
Cisplatinum was obtained from Sicor, Inc.
Antibodies
The anti-PTEN mouse monoclonal antibody (A2B1,
Santa Cruz), anti-PTEN rabbit polyclonal antibody
(#9552, Cell Signaling), anti-AU5 monoclonal antibody
(Covance), anti-Akt, anti-p-S473-Akt, anti-p38 antibo-
dies (Cell Signaling), anti-EGFR, anti-SP1, anti-tubulin,
and anti-HRP-actin (Santa Cruz) antibodies were pur-
chased from the indicated commercial sources.
Saponin subcellular fractionation
Cells were solubilized in 10 mM Tris-HCl, pH 7.4, 150
mM NaCl, 0.01% Saponin, 5 mM EDTA, 2 mM EGTA,
1 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1
mM Na3VO4, 1 mM Na4P2O7, and 10 mM NaF for 20
min on ice. The lysates were centrifuged for 30 min at
18,000 × g. The supernatant was collected as the cytoso-
lic fraction. The pellet was resuspended in 50 mM
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HEPES, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1.5
mM MgCl2, 1 mM EGTA, 10% glycerol, 1 mM PMSF,
10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM Na3VO4,
1 mM Na4P2O7, 10 mM NaF, and centrifuged for 30
min at 18,000 × g. The supernatant was collected as the
membrane fraction.
Nuclear-cytosol fractionation
Nuclear and cytoplasmic fractions were prepared using
the NE-PER fractionation kit (Pierce) according to a
modified manufacturer’s protocol.
Purification of recombinant PTEN from insect cells
Sf9 cells were infected with baculoviruses harboring His-
tagged PTEN WT and E307K expression plasmids for 5-
7 days. Monomeric PTEN was purified as described pre-
viously [16].
Phosphatase activity assay
Recombinant PTEN was incubated with 50 μM syn-
thetic diC8-PI(3,4,5)P3 (Echelon) with or without 50 μM
synthetic diC8-PI(4,5)P2 (Echelon), both in soluble form
for 10 min at 37°C in a final volume of 25 μl. The reac-
tion buffer was in 10 mM DTT and 25 mM Tris-HCl,
pH 8.0. The reaction was stopped with 100 μl of mala-
chite green reagent (Echelon). The amount of phosphate
released was measured by reading the absorbance at 620
nm. For measuring PTEN activity in vitro, 5 × 106 293T
cells were transfected with 15 μg of expression plasmids
using 9 μl of lipofectamine 2000 (Invitrogen). After 48
h, cells were solubilized in 600 μl of a lysis buffer con-
taining 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1%
Triton X-100, 2 mM DTT, 1 mM EDTA, 1 mM PMSF,
10 μg/ml aprotinin, and 10 μg/ml leupeptin. Approxi-
mately 3 mg of total cell extracts were immunoprecipi-
tated with 5 μg of an anti-AU5 antibody for 4 h and
immunocomplexes were affinity absorbed onto 30 μl of
GammaBind G sepharose beads. PTEN phosphatase
activity was then assayed as described above.
Results
Identification of PTEN E307K mutation in MDA-MB-453
During the examination of a panel of human breast can-
cer cell lines for aberrant PTEN expression, we detected
an additional band that migrated at a smaller apparent
molecular weight (~52 kDa) than the WT PTEN protein
(~54 kDa) in the MDA-MB-453 cell line (Figure 1 A).
Short Tandem Repeat (STR) analysis confirmed the
authenticity of this cell line as MDA-MB-453 (data not
shown). Sequencing analysis of the entire PTEN coding
region has identified a single G to A mutation at codon
307 altering the negatively-charged glutamate (GAA) to
a positively-charged lysine (AAA) residue (referred to as
E307K hereafter) (Figure 1 B). The same mutation was
also detected in both genomic and complementary DNA
(cDNA) of this cell line (Figure 1 B). Amino acid E307
was located within the C2 loop of PTEN and was in
proximity to the monoubiquitination site at K289 (Fig-
ure 1 C). Two separate groups have previously identified
the E307K mutation in MDA-MB-453 cell line [17,18],
and not in other breast cancer cell lines examined in
this study [19]. However, both groups have not further
characterized the biological properties of this PTEN
E307K mutant.
To confirm that the faster migrating PTEN band in
MDA-MB-453 represented the PTEN E307K mutant,
we engineered a PTEN E307K mutant cDNA and ecto-
pically expressed in a PTEN-null cell line, PC3. As
expected, the PTEN E307K mutant displayed a similar
mobility as the faster migrating species found in MDA-
MB-453 (Figure 1 D). By both mass spectroscopy and
phosphatase treatment, we failed to identify evidence of
post-translational modifications of the PTEN E307K
mutant protein (data not shown). Consistently, E307K
gene products synthesized by in vitro translation reac-
tions, which presumably devoid of all modification
events, still retained a faster motility (data not shown).
Therefore, we conclude that the glutamate to lysine sub-
stitution at codon 307 resulted in a change in the charge
of PTEN and this caused an aberrant mobility on SDS-
PAGE gel. This mobility shift greatly facilitated the abil-
ity to differentiate between WT and E307K proteins in
subsequent studies.
Biochemical and growth suppressing activities of PTEN
E307K
To investigate if the PTEN E307K mutant displayed
altered enzymatic activity, WT and E307K proteins were
epitope-tagged with 6xhistidine and expressed in Sf9
insect cells. Affinity purified recombinant proteins were
subjected to lipid phosphatase assay in the presence of
combinations of PIP2 and PIP3. As shown in Figure 2 A,
while PTEN proteins did not catalyze the release of
phosphate when PIP2 was used as a substrate, both WT
and E307K catalyzed either PIP3 or PIP2 + PIP3 to a
similar extent. To validate this result, both WT and
E307K PTEN cDNAs were tagged with an AU5 epitope
and transiently transfected in 293T cells. As a negative
control, a D92A/C124A catalytic-dead (ΔCat) mutant
was also included. All PTEN isoforms were immunoaffi-
nity purified with an anti-AU5 monoclonal antibody and
subjected to phosphatase assay using PIP3 as a substrate.
Similar to recombination proteins, both WT and E307K
displayed very similar lipid phosphatase activity while
the ΔCat mutant failed to elicit any enzymatic activity
(Figure 2 B).
To address if the lack of differences in enzymatic
activity between WT and E307K proteins could be
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extended to their tumor suppressing activities, both
cDNAs were expressed in both Pten-/- MEFS and a
PTEN-null glioblastoma cell line, U87MG, through ret-
roviral-mediated gene transduction. As shown in Figure
2 C, both WT and E307K were able to exert ~40% and
~75% growth inhibitory effects on Pten-/- MEFS and
U87MG, respectively. From these data, we conclude that
PTEN E307K mutant does not display observable
defects in both intrinsic lipid phosphatase activity and
growth suppressing potential in PTEN-null cells.
PTEN E307K mutant displays higher membrane
localization
Since the C2 domain of PTEN has been implicated in
membrane targeting [10], attempts were made to exam-
ine the level of PTEN E307K on the cell membrane rela-
tive to WT protein. Taking advantage of the mobility
difference between WT and E307K on SDS-PAGE,
MDA-MB-453 cells were fractionated into cytosolic and
saponin-solubilized membrane fractions. We have
previously used this method to investigate the membrane
localization of different PTEN mutants [16]. As shown in
Figure 3 A, the faster migratory species, which repre-
sented the E307K mutant, was readily detectable in the
membrane fraction that was co-localized with EGFR. On
the contrary, the slower migrating species, which repre-
sented the WT protein, was almost undetectable. This
data is consistent with the transient nature of PTEN at
the plasma membrane reported previously [20]. As a lipid
phosphatase, the higher level of PTEN E307K on the cell
membrane would predict a greater suppression of the
PI3-K signaling. To test this, Pten-/- MEFS stably expres-
sing WT and E307K were analyzed for the activation
state of Akt. As predicted, while WT PTEN repressed p-
Akt level by ~4.5-fold, the E307K mutant displayed a
great suppression of ~6-fold (Figure 3 B). Of note, both
WT and the E307K proteins were expressed to a similar
level. Since MDA-MB-453 was derived from a breast car-
cinoma, we sought to express the E307K mutant in a
breast cancer cell line. For this, WT and E307K
Figure 1 Aberrant PTEN protein species in MDA-MB-453. (A) Western blotting analysis of PTEN in human breast cancer cell lines. The faster
mobility species in MDA-MB-453 is highlighted with an arrow. Actin was used as a loading control. (B) Sequencing analysis of exon8 of PTEN
using genomic DNA and cDNA derived from MDA-MB-453 showing the G to A substitution at codon 307 altering the glutamate (E) residue to a
lysine (K). (C) Schematic representation of PTEN depicting the catalytic domain (CAT) and the C2 loop with the ubiquitination (Ub) site at K289
and the E307K mutation shown. (D) Both wild-type (WT) and E307K mutant were transfected in a PTEN-null cell line, PC3. Note the faster
migrating E307K mutant. All membranes were probed with the monoclonal anti-PTEN antibody (A2B1).
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expression plasmids were electroporated in a PTEN-posi-
tive MCF7 cell line. Similar to Pten-/- MEFS, the E307K
mutant was significantly more effective in attenuating p-
Akt level than WT protein (Figure 3 C). This effect was
unlikely to be an artifact of overexpression as the levels
of ectopic PTEN were only between 3-5 fold. Also, since
electroporation only achieved 60-70% transfection effi-
ciency, the ability of E307K mutant in suppressing p-Akt
could have been greater.
Since both WT and the E307K mutant were co-
expressed in MDA-MB-453, it would be necessary to
evaluate the activation state of the PI3-K signaling path-
way in this cell line. Serum deprivation did not result in
altered p-Akt suggesting that the PI3-K pathway was
constitutively active (Figure 3 D, upper panel). Treat-
ment with the PI3-K inhibitor, LY294002, resulted in
the complete abolishment of p-Akt signals within 30
mins. In addition, treatment with the mTOR inhibitor,
Figure 2 Biochemical and biological properties of PTEN E307K mutant. (A) The phosphatase activity of the indicated PTEN isoforms was
measured in the presence or absence of PIP2 using the malachite green phosphatase assay with PIP3 as the substrate. (B) Vector control (C), WT,
E307K, and ΔCat expression plasmids were transfected in 293T cells. PTEN proteins were immunoprecipitated with an anti-AU5 antibody and
immobilized on sepharose beads. Phosphatase activity was measured in triplicates using the malachite green assay with PIP3 as the substrate.
The relative levels of PTEN isoforms in the immunoprecipitates were monitored by a polyclonal anti-PTEN antibody (insert). Similar data was
reproduced in an additional experiment. (C) Vector control (C), WT, and E307K cDNAs were transduced into Pten-/- MEFS (left panel) and U87MG
(right panel) cells through retroviral-mediated gene transfer. Puromycin (1 μg/ml) resistant mass cultures were analyzed for relative proliferative
capacity after 6 days in cultures. The fold-increase in cell numbers was measured by cell counting. Data represents triplicated measurements
from a single experiment. Bars, SD. *, p < 0.05. ***, p < 0.0005.
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rapamycin, stimulated Akt activation through the inacti-
vation of an S6K-mediated negative feedback loop [21].
Thus, PI3-K pathway is constitutively active in MDA-
MB-453 due most likely to an oncogenic event located
at or upstream of PI3-K.
PTEN E307K mutant has enhanced polyubiquitination
The PTEN C2 loop is an unstructured domain harbor-
ing a single monoubiquitination site at K289 [13]. With
the close proximity to E307, we speculated that the Glu
to Lys substitution at codon307 might constitute a de
novo ubiquitination site and this prompted us to test if
PTEN E307K displayed aberrant ubiquitination pattern.
For this, we have tested the ability of NEDD4-1, a
PTEN E3 ligase [13] in mediating ubiquitination of
PTEN recombinant proteins purified from baculovirally-
infected Sf9 insect cells. As shown in Figure 4 A,
NEDD4-1 catalyzed a more extensive polyubiquitination
of E307K as early as 30 minutes when compared to WT
(Figure 4 A, compare lane 5 and 6). Also, an additional
polyubiquitinated species at +3 position was detected
only in the E307K protein (Figure 4 A, lane 6).
Figure 3 Suppression of Akt by PTEN E307K mutant. (A) MDA-MB-453 cells were solubilized in 0.01% saponin-containing buffer. The
membrane (Mem) and cytosolic (Cyt) fractions were resolved on SDS-PAGE gel and probed with an anti-PTEN monoclonal antibody (A2B1). The
purity of the cytosolic and membrane fractions was confirmed with antibodies against tubulin and EGFR, respectively. (B) Pten-/- MEFS were
transduced with the indicated retroviral expression plasmids. Cell lysates were prepared from cell lines and subjected to Western blotting
analysis using the indicated antibodies. (C) MCF7 cells were electroporated with the indicated expression plasmids and total cell extracts were
prepared for Western blotting analysis. Results from three independent experiments were quantified (right panel). Bars, SE. *, p < 0.05. (D) MDA-
MB-453 cells were cultured in the presence or absence of 10% FBS. Cell extracted were prepared and the levels of p-Akt and c-Akt were
monitored by Western blotting analysis (upper panel). MDA-MB-453 cells were treated with LY294002 (middle panel) or rapamycin (lower panel) at
the indicated concentrations and durations. The activation states of Akt were monitored by Western blotting analysis with actin as a loading
control.
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Furthermore, when similar reaction was conducted in
the presence of a defective ubiquitin (Ub-KO), a E307K
(+3) species at ~72 kDa was already observed when only
E1 and E2 components were present (Figure 4 B, lane
3). This could be due to residual E3 ligase activity co-
purified from Sf9 as has been reported before [13]. Since
Ub-KO could not be polyubiquitinated, the number of
bands signifies the number of ubiquitination site. Based
on these results, both WT and E307K have three Ub
sites. More significantly, the addition of E3 enhances the
intensity of the +3 band in E307K when compared to
WT. Thus, we conclude from these studies that E307K
promotes ubiquitination. We further hypothesize that
the preferential ubiquitination at E307K may set up a
“decoy” effect, potentially disrupting monoubiquitination
at K289 and nuclear import.
PTEN E307K mutant displays reduced nuclear localization
A previous study has identified K289 as a site for mono-
ubiquitination and important for PTEN nuclear target-
ing capacity [13]. The close proximity of E307K to K289
and the aberrant ubiquitination pattern observed with
E307K have prompted us to investigate if the E307K
mutant altered nuclear localization. MDA-MB-453 cell
extract was fractionated into cytosolic and nuclear frac-
tions. As shown in Figure 5 A, the slower migrating spe-
cies, which represented the WT protein, was the only
prominent band in the nuclear fraction. On the con-
trary, both WT and E307K mutant were present in the
cytosolic fraction with the E307K protein at relative
higher level than WT. This data suggests that the
E307K mutant is defective in nuclear import. To validate
this result, PTEN cDNAs were transiently transfected in
MCF7 breast cancer cells and subjected to subcellular
fractionation. The nuclear-to-cytosol ratio was reduced
by 19.7% for the E307K mutant when compared to the
WT protein (Figure 5 B). Statistical analysis revealed a
significant difference only when one-tailed t-test was
used to predict a decrease in nuclear localization. How-
ever, no significant difference was obtained with two-
tailed analysis. This marginal difference could be due to
cell-type specific differences between MDA-MB-453 and
MCF7.
Previous studies have alluded to the ability of nuclear
PTEN in regulating genome integrity and growth sup-
pression [22-25]. The fact that the E307K mutant was
excluded from the nuclear compartment has led us to
examine if cells expressing this PTEN mutant could
have altered sensitivities to conventional chemothera-
peutic agent. To test this, Pten-/- MEFS stably expressing
WT and the E307K mutant were tested. Under
untreated conditions, all these cells have undetectable
sub-G1 cells, which were presumably the apoptotic frac-
tion (Figure 5 C). Exposure to 5 μM cisplatinum
resulted in the appearance of 4% of sub-G1 apoptotic
cells in parental Pten-/- MEFS. On the other hand, the
re-expression of WT PTEN increased this to 8.8%. How-
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Figure 4 Ubiquitination of PTEN E307K by NEDD4-1. Recombinant WT and E307K PTEN were incubated with either Ub-WT (A) or Ub-KO (B)
under the conditions indicated. Reactions were resolved on SDS-PAGE and probed with an anti-PTEN polyclonal antibody (#9552). The amount
of PTEN in each reaction is shown (lower panels).
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E307K expressing cells. This difference was unlikely to
be the result of protein expression since both WT and
the E307K mutant were expressed to a similar level (Fig-
ure 5 D). Thus, these results implicate a role for E307K
in conferring chemoresistance.
Discussion
In this report, we have characterized a unique PTEN
C2 loop mutant present in a widely used human meta-
static carcinoma cell line, MDA-MB-453. This tumor
was originated from a 42 year old female diagnosed
with breast cancer in 1970 at MD Anderson Cancer
Center [26]. A right mastectomy was performed fol-
lowed by radiation and chemotherapy. Tumor relapse
was recorded in 1974 and after further treatments, the
patient died from the disease in 1976. MDA-MB-453
represents a molecular apocrine breast cancer, which is
estrogen receptor-negative but androgen receptor-posi-
tive, and is commonly detected in patients with CS
[27,28]. However, we do not have evidence that the
E307K mutation represents a germ line mutation simi-
lar to those found in CS patients. The lack of access to
germ line tissues hampers our efforts in addressing
this possibility.
Figure 5 Aberrant nuclear localization of PTEN E307K mutant. (A) Total cell lysate (Lys) from MDA-MB-453 was fractionated into cytosolic
(Cyt) and nuclear (Nuc) fractions with the NE-PER kit (Pierce, IL). Tubulin and Sp1 were used as cytosolic and nuclear markers, respectively. Similar
results were obtained from two independent experiments. (B) MCF7 cells were transfected by lipofection with the indicated expression plasmids
and cell lysates were fractionated after 24 h. Purity of the cytosolic and nuclear fractions was confirmed with p38 and Sp1, respectively. Results
represent data from two experiments performed in duplicates. Bars, SE. *, p < 0.05, one-tailed t-test (right panel). (C) Pten-/- MEFs expressing WT
and E307K were treated with PBS (upper panels) or 5 μM cisplatinum (+CP)(Sicor Inc., CA) for 48 hours. Cells were stained with PI. Note the
reduction in the % of sub-G1 cells in E307K+CP. (D) Western blotting analysis of PTEN expression. Anti-PTEN polyclonal antibody (#9552) was
used in all panels. Abbreviations: C, control. *, background signals.
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Mutations in PTEN C2 loop are not without prece-
dent. As mentioned above, a K298E mutation was
uncovered in a CS patient and the nuclear PTEN levels
in the dysplastic intestinal polyps were reduced [12].
More interestingly, PTEN C2 loop is highly acidic in
nature with 10 out of 32 (~31%) amino acids are either
glutamate or aspartate residues. The substitution with a
basic lysine residue at E307 is expected to introduce a
considerable change to the charge surfaces. Indeed, a
search of the Sanger Tumor Gene Mutation Database
has identified similar E to K substitutions at codons
E284, E288, and E291. Coincidentally, these mutations
were either from endometrial or vulva cancers [29-31].
This cluster of E to K mutations highlights the likeli-
hood that C2 loop mutations play a role in either the
initiation or progression of certain human malignancies.
It is also note worthy that there was no evidence of a
loss of heterozygosity in the MDA-MB-453 tumor as
the WT protein species is expressed to a similar level.
Whether the E307K mutant can act as a dominant act-
ing oncogene or has dominant inhibitory effects on the
WT counterpart is currently unknown. Alternatively,
haploinsuffiency may play a role in the progression of
the MDA-MB-453 tumor as has been demonstrated for
the PTEN tumor suppressor gene [32].
The E307K mutant displays similar lipid phosphatase
activity as the WT protein. This is not surprising since
eliminating the 24-aa C2 loop between aa286-309 did
not significantly altered PTEN enzymatic activity and
membrane binding affinity [11]. The finding of a higher
level of the E307K mutant in the saponin soluble mem-
brane fraction is intriguing. One possibility is that the
substituted lysine may serve as a de novo binding inter-
face with the negatively charged membrane. Previously,
our group and others have identified phosphorylation
sites in the PTEN C-terminal tail that may serve to
mask C2 domain from the plasma membrane [16,33,34].
One speculation is that E307K may serve as a decoy
binding site for C-terminal tail and thereby unmasking
the C2 domain for membrane targeting. Demonstrating
this would need biophysical evidence but will pose con-
siderable challenge due to the unstructured nature of
the C2 loop [11].
The greater membrane localization of the E307K
mutant is consistent with the observation of greater sup-
pression of p-Akt levels in both Pten-/- MEFS and MCF7
cells. This finding is, however, inconsistent with the fact
that E307K shows similar growth suppressing activity as
WT. A plausible explanation is that Akt activation does
not correlate with cell proliferation in Pten-/- MEFS.
Alternatively, the threshold of repressed p-Akt level suf-
ficient for growth suppression is rather low for differ-
ences to be registered. Also, it is counterintuitive that
breast cancer cells would acquire a mutation in PTEN
that has greater ability in suppressing the PI3-K path-
way. At present, we do not have a solid explanation to
this paradox. One speculation is that since Akt1 has
been shown to block breast cancer cell migration
[35,36], the presence of a E307K mutant may repress
Akt1 activation and promote metastatic growth. An
alternative explanation is that the persistent suppression
of PI3-K > Akt pathway in cells harboring the E307K
mutant may promote secondary mutations that can sub-
vert this repression. Indeed, MDA-MD-453 harbors a
H1047R oncogenic mutation in the PIK3CA gene [18].
This is consistent with the fact that the PI3-K inhibitor,
LY294002, could completely abolish p-Akt in this tumor
line.
The heightened polyubiquitination observed with the
E307K mutant reaffirms the role of C2 loop in the post-
translational modification of PTEN. However, it is not
clear which sites are being modified. It is tempting to
speculate that the aberrant polyubiquitination of E307K
can result in PTEN nuclear exclusion since monoubiqui-
tination appears to be critical for nuclear import [12]. In
addition, the increase in polyubiquitination does not
result in greater degradation of the PTEN E307K pro-
tein since its level is almost identical to that of WT.
Several cellular functions have been ascribed to
nuclear PTEN including p53-dependent oxidative stress
response [22], protection against DNA double strand
breaks [23], and growth suppression through binding to
the APC-CDH1 complex [37]. Currently, it is unclear if
PTEN E307K mutant binds p53 or APC-CDH1 with
altered affinity. The inability of PTEN E307K mutant in
sensitizing cells to cisplatinum would argue for a nega-
tive role of nuclear PTEN in promoting DNA damage
response. Given the pro-survival function of Akt, our
data is inconsistent with the fact that PTEN K307E
mutant possesses a greater ability in suppressing Akt
activation in Pten-/- MEFS. To resolve these issues,
clearly defining the Akt isoforms being regulated would
be important. To clearly define the role of E307K muta-
tion, it may be necessary to eliminate this mutant PTEN
allele by either gene silencing or somatic gene knockout
in MDA-MB-453. In summary, this study provides an
initial characterization of a PTEN C2 loop mutant pre-
sent in a breast cancer cell line. To our knowledge,
MDA-MB-453 is the only known cell line that harbors a
PTEN C2 loop mutation. Thus, this study highlights the
availability of a commonly used breast cancer cell line
for future research into the role of PTEN C2 loop in
nuclear/cytosol partitioning.
Conclusions
We have identified a mutation within the C2 loop of
PTEN in a human metastatic breast cancer cell line,
MDA-MB-453. The E307K mutant protein displays
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subtle changes in biochemical and biological properties
unlike other PTEN mutations that inactivate its catalytic
activity. The major defect is associated with aberrant
subcellular distribution of the cytosolic pool of PTEN,
being preferentially targeted to the plasma membrane
but excluded from the cell nucleus. These changes may
predispose breast epithelial cells to transformation and
the acquisition of chemoresistance. This mutation is
highly reminiscent to those subtle C2 loop mutations
found in CS patients. These findings also highlight the
importance of future work in further unraveling the
tumor suppressing effects of nuclear and membrane
PTEN and how their interplay is differentially regulated
in different cancer types. As a widely used metastatic
breast carcinoma cell line, MDA-MB-453 will be a valu-
able resource for future studies related to the regulation
of PTEN subcellular distribution.
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